Table 5.
All the QM statistics for whether the moderators have a significant effect on corticosteroid-free clinical remission rate
| (A) Corticosteroid-free clinical remission week 16 | |||
| Moderator | QM | df | p |
| Study design | 0.2123 | 1 | 0.6449 |
| Number of center | 0.5493 | 1 | 0.4586 |
| Prior anti-TNFα | 0.5493 | 1 | 0.4586 |
| Prior more than two anti-TNFα | 0.5493 | 1 | 0.4586 |
| Prior VDZ | 0.5493 | 1 | 0.4586 |
| Severity | 0.5493 | 1 | 0.4586 |
| Concomittant IM | 0.5493 | 1 | 0.4586 |
| Concomittant steroid | 0.5493 | 1 | 0.4586 |
| Publish style | 0.5493 | 1 | 0.4586 |
| (B) Clinical remission month 6 | |||
| Moderator | QM | df | p |
| Study design | 0.0001 | 1 | 0.9918 |
| Concomittant IM | 0.0049 | 1 | 0.9441 |
| Concomittant steroid | 0.0637 | 1 | 0.8008 |
| (C) Clinical remission month 12 | |||
| Moderator | QM | df | p |
| Prior anti-TNFα | 0.6304 | 1 | 0.4272 |
| Prior VDZ | 2.6149 | 1 | 0.1059 |
| Concomittant IM | 0.5228 | 1 | 0.4697 |
| Concomittant steroid | 0.5238 | 1 | 0.4692 |
| Publish style | 0.3312 | 1 | 0.5649 |
QM: test statistic for the omnibus test of moderators
TNF: tumor necrosis factor
df: degrees of freedom
VDZ: vedolizumab
TOF: tofacitinib
IM: immunomodulator